I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Thyroid cancer is the most prevalent endocrine malignancy accounting for 1% of cancers worldwide. More than 95% of thyroid cancer are well differentiated tumors that respond to surgery followed by radioactive iodine (RAI) therapy and thyroid hormone suppression. Anaplastic thyroid cancer constitutes \<2% of thyroid cancers but carries almost 100% mortality.\[[@ref1][@ref2]\]

ATCs originate from follicular cells and may either derive de novo or from pre-existing well differentiated thyroid cancers (WDTCs) such as papillary thyroid carcinomas (PTCs), follicular thyroid carcinomas (FTCs) or even from poorly-differentiated thyroid carcinomas (PDTCs) by accumulation of various genetic alterations.\[[@ref3][@ref4][@ref5][@ref6][@ref7][@ref8]\] Numerous studies have explored ATC mutational landscape and have increased our understanding of the molecular pathogenesis of thyroid cancer. Among the genetic alterations involved in thyroid tumourigenesis, *BRAF* mutations, *RAS* mutations and *RET* rearrangements are important in differentiated thyroid carcinomas.

The beneficial effect of BRAF inhibition in ATC with activating BRAF mutations has been recently reported.\[[@ref9][@ref10]\] Other genetic alterations include gain of function mutations in the PIK3CA gene, mutations in the CTNNB1, loss of function alterations of tumor suppression genes such as PTEN, and mutation or inactivation of P53 gene. Hence the knowledge of the tumor mutation status is needed for optimizing and tailoring the treatment with kinase inhibitors as well as in understanding the heterogeneity and failure of existing treatment approaches.\[[@ref9][@ref11]\] We sought to study the genetic alterations in ATC with the aim of finding out whether there is any difference in mutations in those ATC which are thought to develop from a pre-existing DTC as compared to those develop de-novo and to look for any clinco-pathological correlation with a particular mutation/inactivation.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Sample Collection {#sec2-1}
-----------------

Study was conducted at department of endocrine surgery, SGPGI. Data of all patients diagnosed with anaplastic thyroid carcinoma from 1990 to 2018 were collected and 34 patients with a complete clinicopathological record and adequate tissue samples for genetic analysis were selected for the study. The cases with incomplete records and with poor tissue samples were excluded from the study. Formalin Fixed Paraffin Embedded (FFPE) blocks were taken out for genetic analysis. The study was approved by Institutional Ethics committee. Institute ethics committee: JAN 2017. Ethics number 2017-3-IMP-95.

Methods of gene analysis {#sec2-2}
------------------------

### DNA isolation {#sec3-1}

The tumor areas were confirmed and marked from the slides stained by Heamatoxylin and eosin stain (H and E stain). Eight sections of 10 micron from each FFPE tissue blocks were subjected to DNA extraction using QIAamp FFPE tissue kit (Qiagen, Germany). The quality and quantity of the DNA was measured by using the Nano Drop 2000c (Thermo Fisher Scientific, US).

### RNA isolation {#sec3-2}

Total RNA was isolated from 34 FFPE ATC tissues by using Recover All Total Nucleic Acid isolation kit for FFPE (Thermo Fisher Scientific, US). Quantity and quality were measured by Nano Drop 2000c (Thermo Fisher Scientific, US and stored in -80°C). Yield and quality of RNA was not affected by the procedure and storage. Further cDNA was synthesized by using Revert Aid First strand cDNA synthesis kit (Thermo Fisher Scientific, US).

Point mutation analysis {#sec2-3}
-----------------------

The presence of *BRAF V600E and K601E, NRAS codon 61, HRAS codon 61, and KRAS codons 12 and 13* point mutations was analyzed using two different techniques.

PCR-RFLP and sequencing for BRAF {#sec2-4}
--------------------------------

The most common BRAF V600E mutation reported in thyroid carcinomas is confined to exon 15. We therefore amplified BRAF exon 15 by polymerase chain reaction (PCR) using the following primers: forward \'5GCTTGCTCTGATAGGAAAATGAG3\'; reverse \'5GATACTCAGCAGCATCTCAGG3\'. The denatured PCR products were electrophoresed \[[Figure 1a](#F1){ref-type="fig"}\] and digestion of the 237-base pair (bp) PCR fragment with restriction endonuclease TspRI showed 3 major bands of 117 bp, 87 bp, and 33 bp for the wild type allele \[[Figure 1b](#F1){ref-type="fig"}\]. The T1799A mutation abolished the restriction sites, which resulted in a prominent band of 237 bp from the mutant allele and residual bands from the normal allele.\[[@ref12]\] Randomly selected three BRAF positive samples were sequenced \[[Figure 1c](#F1){ref-type="fig"}\] using Applied Biosystems 3500 genetic analyzer and reconfirmed the presence of BRAF mutations.

![(a) BRAF gene amplicon of 237 bp (b) Representative figure showing wild type and heterozygous BRAF mutation (c) Presence of BRAF V600E confirmed by sequencing](IJEM-23-480-g001){#F1}

RET/PTC rearrangements: RET/PTC1, RET/PTC3, rearrangements was detected from RNA by RTPCR with primers designed to flank the respective fusion point. Quality of RNA in each sample was assessed by amplification of the -GAPDH gene. Primers and Taqman probe for RET/PTC1 were used as described previously in detail.\[[@ref12]\]

RAS and PI3CA mutation detection {#sec2-5}
--------------------------------

Point mutations in codons 12/13 of the H-RAS, K-RAS and codon 61 of N-RAS genes were analyzed by Sanger sequencing method \[[Figure 2](#F2){ref-type="fig"}\]. DNA isolated from the FFPE tissue was amplified for KRAS, HRAS and NRAS using the following PCR primers: codon 12/13 KRAS-A (5′-GGCCTGCTGAAAATGACTGA-3′) and D (5′-TAGCTGTATCGTCAAGGCAC-3′), codon 12/13 of HRAS 5′-TGAGGAGCGATGACGGAA-3′ and 5′-GCGCTAGGCTCACCTCTAT-3′, codon 61 NRAS: 5′-CCTGTTTGTTGGACATACTG-3 and 5′-CCTGTAGAGGTTAATATC CG-3′.

![RAS mutations Q61K and Q61R mutation](IJEM-23-480-g002){#F2}

Using specific primers (exon 9 forward, 5′-ATCATCTGTGAATCCAGA-3′; exon 9 reverse, 5′-TTAGCACTTACCTGTGAC-3′; exon 20 forward, 5′-TGACATTTGAGCAAAGACC-3′; and exon 20 reverse, 5′-GTGTGGAATCCAGAGTGA-3′), the portions of exon 9 and 20 of PI3K gene were amplified. Further, these portions were sequenced using ABI capillary sequencer.

P53 IHC {#sec2-6}
-------

The sections were cut at 4μ thickness on polylysine coated slides, deparaffinised and rehydrated in graded alcohols. Antigen retrieval was done in EDTA buffer at pH 8.9 followed by endogenous peroxidase blocking with 3% H~2~O~2~. Sections with primary monoclonal antibody for P53 (dilution - 1:200, source *P* 53 polyclonal antibody from Cell Signaling Technology, United States) were incubated for 1 hour at room temperature. Secondary antibody (UltraVision Quanto Detection System, Thermo Fisher) was incubated for 30 minutes at room temperature. Diaminobenzidine was used as chromogen and followed by counterstaining with Mayer\'s hematoxylin and mounting in DPX. Nuclear expression was considered as positive staining.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 34 patients were studied. Mean age was 58.6 ± 11.6 years. Female:male ratio was 1.8:1 \[[Table 1](#T1){ref-type="table"}\]. 60% had history of previous goiter.

###### 

Age and sex distribution of patients (*n*=34)

  Parameters                
  ------------------------- --------------
  Age (years)               58.6 (36-80)
  Sex (F:M)                 1.8:1
  H/o goitre-*n* (%)        15 (44.1)
  Thyroid function          
   Euthyroid- *n* (%)       23 (67.6)
   Hyperthyroid- *n* (%)    7 (20.5)
   Not available- *n* (%)   4 (11.7)

Most common presenting symptom was rapidly growing thyroid mass followed by dyspnea, dysphasia and hoarseness of voice. The extent of disease was local, locoregional and metastatic in 32, 35 and 33% respectively \[Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}\]. 57.6% were euthyroid, 20.5% were hyperthyroid while functional status was not available in 4 patients. FNAC was suggestive of ATC only in 52.9% cases \[[Table 5](#T5){ref-type="table"}\]. 15 (44%) patients were operated \[[Table 6](#T6){ref-type="table"}\].

###### 

Presenting complaints (*n*=34)

  Symptoms              Frequency   Percent
  --------------------- ----------- ---------
  Neck mass             29          85.3
  Dyspnoea              1           2.9
  Hoarseness of voice   2           5.9
  Pain                  1           2.9
  Recurrent goiter      1           2.9

###### 

Overall symptoms (*n*=34)

  Symptoms              No.   Percentage
  --------------------- ----- ------------
  Dyspnea               17    50
  Dysphagia             12    35.2
  Hoarseness of voice   12    35.2
  Cervical pain         5     14.7
  Weight loss           5     14.7
  VC palsy              6     17.6

###### 

Extent of disease (*n*=34)

  Parameters                 *n* (%)
  -------------------------- ---------------
  Tumour size                8.0 (4.0-15)
  Cervical lymphadenopathy   18/34 (52.9%)
  Extent of disease (%)      
  Local                      32.4
   Locoregional              35.3
   Metastatic                265
  Sites of metastasis (%)    
   Lung                      66.7
   Bone                      22.2
   Liver                     11.1

###### 

Fine needle aspiration cytology (*n*=34)

  FNAC finding                   *n* (%)
  ------------------------------ -----------
  Anaplastic thyroid cancer      18 (52.9)
  Follicular neoplasm            1 (2.9)
  Inadequate                     1 (2.9)
  Medullary thyroid cancer       4 (11.8)
  N/A                            4 (11.8)
  Poorly differentiated cancer   1 (2.9)
  Positive for malignancy        3 (8.8)
  Papillary thytoid cancer       1 (2.9)
  Squamous cell carcinoma        1 (2.9)

###### 

Surgical procedure (*n*=14)

  Surgical Procedure            *n* (%)
  ----------------------------- ----------
  Debulking                     2 (5.9)
  Near Total Thyroidectomy      1 (2.9)
  Total Thyroidectomy           7 (20.6)
  Total Thyroidectomy + CCLND   2 (5.8)
  Total Thyroidectomy + MRND    3 (8.8)

BRAF V600E mutations were observed in 10/34 (29.4%). Interestingly, all three ATC patients with DTC components had previous history of goiter with rapid increase in size and BRAF V600E mutation, while BRAF was positive only in 7/31 (22.5%) of patients with no DTC component. Mean survival of 3.5 months in BRAF positive cases in comparison to 5.5 months in BRAF negative ATC. RAS mutations were found to be positive in 5.8%, and none had RET-PTC/PI3CA mutations. P53 mutation was positive in 7 patients. 3 patients presented with history of rapid increase in size of previous goiter while rest 4 patients presented with rapidly increasing thyroid swelling of 1 to 3 months \[[Table 7](#T7){ref-type="table"}\]. At presentation 2 patients has disease localized to thyroid, 4 has loco-regional disease and one patient presented with metastasis. 5 out of these 7 patients were operated (Total thyroidectomy: 3, thyroidectomy with neck dissection: 2). Mean survival was 4 months (1-6 months). There were no concomitant mutations present however, immunohistochemistry of P53 was positive in 3 BRAF mutated cases (3/7) and one RAS positive patient (1/7) \[[Figure 3](#F3){ref-type="fig"}\].

###### 

Genetic profile (*n*=34)

  Genes     No of positive cases   Percentage
  --------- ---------------------- ------------
  BRAF      10                     29.4%
  *RAS*     4                      11.76%
  PI3CA     0                      0
  RET/PTC   0                      0
  *p53*     7                      20.5

![(a) Negative p53 immunostaining in poorly differentiated carcinoma of thyroid (Magnification - 20X, IHC). (b) Strong nuclear expression (arrow) of p53 in epithelial cells of anaplastic carcinoma. The interspersed lymphomonuclear infiltrate is negative for p53. (Magnification - 20X, IHC) (c) Stong nuclear expression of p53 in spindled and epithelial cells along with tumor giant cells (arrow) in anaplastic carcinoma (Magnification - 20X, IHC)](IJEM-23-480-g003){#F3}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Anaplastic thyroid cancer has poor survival despite aggressive conventional therapy. Ina previous publication from the authors\[[@ref13]\] mean survival in a series of 100 patients was only 3 months. It is still therefore a "viper in the thyroid cancer pit."\[[@ref14]\] Thus there is a need to look beyond the conventional forms of treatment such as molecular therapy. Genetic alterations are highly prevalent in anaplastic thyroid cancer in comparison to differentiated thyroid cancer. Zhi Liu\[[@ref15]\] et al. has shown that overall, 46 of 48 ATC (95.8%) harboured at least one genetic alteration either in MAP kinase pathway or PIK3/Akt pathway. In our study overall 21 of 34 (67%) patients tested positive for at least one mutation. BRAF V600E mutations were observed in 10/34 (29.4%). It was the most common mutation in our study.

BRAF mutation has been documented to be the most common mutation in papillary thyroid cancer.\[[@ref16][@ref17]\] The high prevalence of BRAFV600E mutation in ATC supports the hypothesis that many ATCs actually represent a progressive malignant degeneration of BRAF-mutated, well-differentiated thyroid carcinomas.\[[@ref18]\] This gene is a pivotal component of the MAPK pathway and reduces the activity of p21kip1 in thyroid tumors, stimulating the cell cycle machinery. Although clinical studies of BRAF inhibitors in advanced non RAI-responsive differentiated thyroid carcinomas have shown encouraging results with frequent early responses, in a relevant fraction of patients this effect was of limited duration, with frequent relapse or no response. Interestingly, all three ATC patients with DTC components had previous history of goiter with rapid increase in size and BRAF V600E mutation, which again support the hypothesis of origin of ATC from progressive degeneration of differentiated thyroid cancer.

The high prevalence of BRAFV600E mutation in ATC supports the hypothesis that many ATCs actually represent a progressive malignant degeneration of BRAF-mutated, well-differentiated thyroid carcinomas.\[[@ref18]\] In our study, BRAF mutations were found in 29.4% of cases. All mutations were p.V600E and were mutually exclusive to (K-H-N)-RAS mutation. Despite a well-known correlation between the presence of a BRAF mutation and tumor aggressiveness in PTCs,\[[@ref19][@ref20]\] BRAF mutations are less frequent in ATCs (as in our cohort) than in PTCs (prevalence of 45-50%).\[[@ref21][@ref22]\]

Since BRAF mutations do not appear to occur during tumor dedifferentiation but are relatively early and frequent events in PTC carcinogenesis,\[[@ref23]\] all ATCs may not be derived from PTCs. Therefore BRAF mutations seem to most prevalent mutation in PDTC.\[[@ref24]\] BRAF-mutant cells have been reported to be MEK dependent and selectively more sensitive to MEK inhibition than either RAS-mutant or both BRAF and RAS wild-type cells. As MEK is a key downstream signaling mediator of the MAP-kinase pathway, the use of co-inhibitors has been proposed in anticancer therapies.\[[@ref25]\]

An obstacle to the efficacy of treatments based on the inhibition of BRAF V600E is the presence of activating mutations of RAS. This proto-oncogene is located upstream RAF in the MAPK cascade. Activating mutations of this protein reactivate the MAPK pathway, making BRAFV600E inhibition inefficient.\[[@ref18]\] The high prevalence of RAS activating mutations in ATC (60%) makes the inhibition of the MAPK pathway by kinase inhibitors unsuccessful. Moreover, papillary thyroid carcinoma and ATC exhibit concomitant BRAFV600E and RAS mutations, although a rare occurrence.\[[@ref19][@ref20]\] In light of these considerations, the pharmacological inhibition of the MAPK pathway looks less promising than the inhibition of the PI3K/Akt/mTOR pathway.

P53 was second most common mutation in our study found in 7 of 34 (20.5%) patients. This mutation has been suggested to be associated with de novo origin of anaplastic thyroid cancer. In contrast to our study in which BRAF was the most common mutation, few other studies suggest that p53 is the most common mutation in anaplastic thyroid cancer.\[[@ref21]\] The prevalence rate in the literature ranges from 48%\[[@ref24]\] to up to 70-80%.\[[@ref26][@ref27]\] It has been suggested that wild type p53 gene helps in expression of sodium iodide symporter I thyroid follicular cells allowing radioiodine therapy. Inactivating mutation in p53 leads to loss of sodium iodide symporter and radio-iodine avidity, thereby resulting in poor prognosis\[[@ref28]\] In our study P53 mutation was positive in 7 patients. 3 of 7 patients presented with history of rapid increase in size of previous goiter while rest 4 patients presented with rapidly increasing thyroid swelling of 1 to 3 months. At presentation, 2 patients has disease localized to thyroid, 4 had loco-regional disease and one patient presented with metastases. Mean survival of these 7 patients was 4 months.

Incidence of RAS mutation is relatively low in anaplastic thyroid cancer. These mutations are frequent in a variety of thyroid tumors from benign follicular adenomas (20-25%) to aggressive ATCs (20-30%) indicating a role in early tumorigenesis.\[[@ref29]\] It was found to be positive in 5.8% of our cases. Libero Santarpia et al. in 2008\[[@ref30]\] studied 36 samples of ATCs and found RAS mutation in 6% of cases which is close to that of our study. On the other hand, RAS mutations are the commonest molecular alteration in poorly differentiated carcinoma.\[[@ref31]\] RAS mutation has not been shown to be associated with overall prognosis in ATC.

The prevalence of PIK3/AKT pathway alteration in our series was much lower than that reported in the literature for ATCs (15-25%) and close to that found for follicular carcinomas.\[[@ref18]\] It is suggested that PIK3CA alterations often cooperate with other Oncogenic events.\[[@ref32]\]

Although RET/PTC rearrangement is a common mutation in papillary thyroid cancer, it is not common in anaplastic thyroid cancer. We analyzed all 3 types of RET/PTC rearrangement in 34 samples. None of the samples tested positive for RET/PTC rearrangement. A single RET mutation has been identified in a series of 22 ATCs,\[[@ref33]\] associated with TP53, CTNNB1 and RASAL1 mutations Roderick M. et al.\[[@ref34]\] analyzed RET/PTC rearrangement in 8 ATC tumor samples and did not find any sample positive.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

BRAF mutation is responsible for majority of ATC originating from or in combination of differentiated thyroid cancer. This provide and indirect evidence of origin of ATC from preexisting DTC. BRAF positive ATC has poor survival than those of BRAF negative cases.
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